TheraRadar

Pharma Intelligence, Simplified

Landscape → Oncology

Bladder Cancer

821 clinical trials

448 active
/
821 total (since 2015)
174
Phase 1 Active
365 total
268
Phase 2 Active
472 total
85
Phase 3 Active
121 total
9
Phase 4 Active
15 total

Top Sponsors (Industry)

Sorted by active Active Done Failed
Merck 11 5 0
AstraZeneca 9 1 0
Pfizer 5 2 10
Mabwell (Shanghai) Bioscience Co., Ltd. 5 0 0
Roche 4 5 3
Ferring Pharmaceuticals 4 1 1
Bristol-Myers Squibb 4 1 1
Johnson & Johnson 4 0 0
UroGen Pharma Ltd. 3 3 1
RemeGen Co., Ltd. 3 3 0
Astellas Pharma Global Development, Inc. 3 1 1
CG Oncology, Inc. 3 2 0
BeiGene 3 1 0
ImmunityBio, Inc. 3 0 1
Relmada Therapeutics, Inc. 3 0 0
NCT05092958 ACTIVE NOT RECRUITING
Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study
National Cancer Institute (NCI) n=654
NCT07000084 RECRUITING
Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy
Alliance for Clinical Trials in Oncology n=330
NCT03775265 ACTIVE NOT RECRUITING
Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer
National Cancer Institute (NCI) n=475
NCT06545955 RECRUITING
A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer
Ferring Pharmaceuticals n=250
NCT04579224 RECRUITING
Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer
National Cancer Institute (NCI) n=184
NCT03244384 ACTIVE NOT RECRUITING
Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer
National Cancer Institute (NCI) n=739
NCT06524544 RECRUITING
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
National Cancer Institute (NCI) n=320
NCT04628767 RECRUITING
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer
National Cancer Institute (NCI) n=249
NCT05987241 RECRUITING
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
National Cancer Institute (NCI) n=992
NCT07393542 RECRUITING
A Trial of SHR-A2102 With Adebrelimab in Locally Advanced or Metastatic Urothelial Carcinoma
Suzhou Suncadia Biopharmaceuticals Co., Ltd. n=462
NCT05538663 ACTIVE NOT RECRUITING
Intravesical BCG vs GEMDOCE in NMIBC
ECOG-ACRIN Cancer Research Group n=870
NCT04559139 ACTIVE NOT RECRUITING
Comparison of Chemotherapy Before and After Surgery Versus After Surgery Alone for the Treatment of Gallbladder Cancer
ECOG-ACRIN Cancer Research Group n=186
NCT07106762 RECRUITING
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
Bristol-Myers Squibb n=470
NCT07129993 RECRUITING
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
Daiichi Sankyo n=630
NCT06510374 RECRUITING
Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
Ferring Pharmaceuticals n=454
NCT07419295 NOT YET RECRUITING
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
Merck Sharp & Dohme LLC n=590
NCT05911295 ACTIVE NOT RECRUITING
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
Seagen, a wholly owned subsidiary of Pfizer n=412
NCT06225596 RECRUITING
Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
BicycleTx Limited n=956
NCT04660344 ACTIVE NOT RECRUITING
A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy
Hoffmann-La Roche n=761
NCT03661320 ACTIVE NOT RECRUITING
A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer
Bristol-Myers Squibb n=855
NCT03682068 ACTIVE NOT RECRUITING
Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer
AstraZeneca n=1,246
NCT03390504 ACTIVE NOT RECRUITING
A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations
Janssen Research & Development, LLC n=629
NCT07097142 RECRUITING
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
NRG Oncology n=486
NCT02516241 ACTIVE NOT RECRUITING
Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer
AstraZeneca n=1,126
NCT06703476 RECRUITING
A Study of Surgical Techniques During Cystectomy
Memorial Sloan Kettering Cancer Center n=530
NCT03967977 RECRUITING
Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma
BeiGene n=420
NCT04165317 ACTIVE NOT RECRUITING
A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer
Pfizer n=1,068
NCT05714202 ACTIVE NOT RECRUITING
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
Janssen Research & Development, LLC n=1,135
NCT07346053 NOT YET RECRUITING
The Impact of Time-of-day Administration of EV/P on Objective Response Rate in Adults With Advanced Bladder Cancer
Guliz Ozgun n=224
NCT06774131 RECRUITING
A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer
UroGen Pharma Ltd. n=70
NCT07342517 NOT YET RECRUITING
A Phase 3 Study of NDV-01 as an Intravesical Administration to Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC), Refractory to First-line Therapy
Relmada Therapeutics, Inc. n=85
NCT06331299 ACTIVE NOT RECRUITING
A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer
UroGen Pharma Ltd. n=99
NCT06111235 ACTIVE NOT RECRUITING
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
CG Oncology, Inc. n=367
NCT07313891 NOT YET RECRUITING
A Study of Adjuvant NDV-01 (Sustained-release Gemcitabine-docetaxel) for the Treatment of Intermediate Risk NMIBC Following TURBT
Relmada Therapeutics, Inc. n=302
NCT03711032 ACTIVE NOT RECRUITING
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
Merck Sharp & Dohme LLC n=1,397
NCT04960709 ACTIVE NOT RECRUITING
Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin
AstraZeneca n=712
NCT05943106 ACTIVE NOT RECRUITING
BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants
AstraZeneca n=100
NCT05726786 RECRUITING
The Role of Preoperative Immunonutrition on Morbidity and Immune Response After Cystectomy (INCyst Trial)
Centre Hospitalier Universitaire Vaudois n=232
NCT06851663 RECRUITING
Trop2-targeted immunoPET Imaging of Solid Tumors
RenJi Hospital n=400
NCT07268339 NOT YET RECRUITING
A Phase III Randomised Control Clinical Trial of Radiotherapy With Radiosensitisation Versus Intravesical Bacillus Calmette-Guerin Therapy for High-risk Non-muscle Invasive Bladder Cancer.
The Christie NHS Foundation Trust n=328
NCT03528694 ACTIVE NOT RECRUITING
Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer
AstraZeneca n=1,018
NCT03732677 ACTIVE NOT RECRUITING
Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC
AstraZeneca n=1,063
NCT06525571 RECRUITING
Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection
Johns Hopkins University n=200
NCT06929286 RECRUITING
A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)
Memorial Sloan Kettering Cancer Center n=125
NCT03036098 ACTIVE NOT RECRUITING
Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer
Bristol-Myers Squibb n=1,314
NCT03022825 ACTIVE NOT RECRUITING
QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer
ImmunityBio, Inc. n=190
NCT07198451 NOT YET RECRUITING
Efficacy of Gemcitabine Submucosal Injection for Preventing Recurrence in Intermediate- and High-Risk Non-Muscle-Invasive Bladder Cancer: A Randomized Trial
Shanghai University of Traditional Chinese Medicine n=320
NCT06124976 RECRUITING
Multicenter Clinical Trial of ST-02 for Ablation of Upper Tract Urothelial Carcinoma
University of British Columbia n=70
NCT06857175 RECRUITING
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Urothelial Carcinoma
Sichuan Baili Pharmaceutical Co., Ltd. n=508
NCT05704244 ACTIVE NOT RECRUITING
Safety and Efficacy of FE 999326 Administered Intravesically to Japanese Subjects With High-grade, BCG Unresponsive, Non-muscle Invasive Bladder Cancer (NMIBC)
Ferring Pharmaceuticals n=25
NCT03924856 ACTIVE NOT RECRUITING
Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)
Merck Sharp & Dohme LLC n=907
NCT03924895 ACTIVE NOT RECRUITING
Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)
Merck Sharp & Dohme LLC n=595
NCT07067749 RECRUITING
Treatment Expedition With MRI Processing and Optimization for Muscle Invasive Bladder Cancer
University of Rome Tor Vergata n=92
NCT02106572 ACTIVE NOT RECRUITING
Therapeutic Instillation of Mistletoe
Abnoba Gmbh n=548
NCT04574960 RECRUITING
Neoadjuvant Upper Tract Invasive Cancer Trial (NAUTICAL)
University Health Network, Toronto n=14
NCT06738251 RECRUITING
A Phase III Study of SHR-A2102 Versus Investigator-selected Therapy in Advanced Urothelial Carcinoma
Shanghai Hengrui Pharmaceutical Co., Ltd. n=402
NCT04865939 RECRUITING
Gemcitabine Versus Water Irrigation in Upper Tract Urothelial Carcinoma
University of Texas Southwestern Medical Center n=132
NCT04452591 ACTIVE NOT RECRUITING
Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
CG Oncology, Inc. n=190
NCT05059522 ACTIVE NOT RECRUITING
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
Pfizer n=68
NCT06879145 RECRUITING
Clinical Study on the Treatment of MIBC Patients With SHR-A2102 Injection Combined With Adebrelimab (SHR-1316)
Suzhou Suncadia Biopharmaceuticals Co., Ltd. n=840
NCT04223856 ACTIVE NOT RECRUITING
Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer
Astellas Pharma Global Development, Inc. n=886
NCT05078047 RECRUITING
Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO
UNICANCER n=646
NCT05506943 ACTIVE NOT RECRUITING
A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)
Compass Therapeutics n=150
NCT06196736 RECRUITING
A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer
Mabwell (Shanghai) Bioscience Co., Ltd. n=432
NCT06214572 RECRUITING
Radiation Therapy in Unresectable Gall Bladder Cancer
Tata Memorial Centre n=249
NCT06493552 RECRUITING
Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors
Vasgene Therapeutics, Inc n=700
NCT03091660 ACTIVE NOT RECRUITING
S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer
SWOG Cancer Research Network n=1,000
NCT02867865 ACTIVE NOT RECRUITING
Perioperative Therapy Preoperative Chemotherapy Versus Chemoradiotherapy in Locally Advanced Gall Bladder Cancers
Tata Memorial Hospital n=124
NCT06364904 NOT YET RECRUITING
A Clinical Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma.
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University n=210
NCT05037279 RECRUITING
Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients with Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC)
Verity Pharmaceuticals Inc. n=540
NCT06696794 RECRUITING
Investigating the Efficacy and Safety of Neoadjuvant Intravesical Instillation of Mitomycin C in Treating High-risk NMIBC Patients
Shaogang Wang n=180
NCT02951325 ACTIVE NOT RECRUITING
Bladder Cancer Adjuvant Radiotherapy Trial
Tata Memorial Centre n=153
NCT04637594 ACTIVE NOT RECRUITING
Trying to Find the Correct Length of Treatment with Immune Checkpoint Therapy
Alliance for Clinical Trials in Oncology n=3
NCT03799835 ACTIVE NOT RECRUITING
Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients
UNICANCER n=517
NCT06671418 ENROLLING BY INVITATION
Primary Percutaneous Stenting Above the Ampulla Versus Endoscopic Drainage for Unresectable Malignant Hilar Biliary Obstruction
Erasmus Medical Center n=148
NCT05243550 ACTIVE NOT RECRUITING
A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
UroGen Pharma Ltd. n=240
NCT06592326 RECRUITING
9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer
Mabwell (Shanghai) Bioscience Co., Ltd. n=460
NCT05833815 RECRUITING
Addition of Everolimus to Standard of Care in Carcinoma Gallbladder
Banaras Hindu University n=56
NCT05822934 ACTIVE NOT RECRUITING
Carboplatin-gemcitabine Versus Cisplatin- Gemcitabine as Neoadjuvant Chemotherapy for Treatment of Muscle Invasive Urinary Bladder Cancer
Assiut University n=20
NCT06327932 NOT YET RECRUITING
HIVEC in Patients With Non-Muscle-Invasive Bladder Cancer
Affiliated Cancer Hospital & Institute of Guangzhou Medical University n=320
NCT06241755 RECRUITING
Clinical Trial for Evaluating the Efficacy and Safety of BCG for Therapeutic Use in the Prevention of Postoperative Recurrence of Medium/High-risk Non-muscle Invasive Bladder Cancer (NMIBC)
Chengdu CoenBiotech Co., Ltd n=412
NCT05302284 RECRUITING
A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma
RemeGen Co., Ltd. n=452
NCT03216525 RECRUITING
Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol
Brigham and Women's Hospital n=136
NCT05810623 NOT YET RECRUITING
Single-Dose Intravesical Chemotherapy After Diagnostic URS
David D'Andrea n=394
NCT04947059 RECRUITING
Effectiveness of an Immediate Postoperative Intravesical Instillation With Either Gemcitabine or Epirubicin in Patients With Urinary Bladder Cancer (Gemcitabine Epirubicin Normal SAline)
University of Thessaly n=180
NCT07413120 COMPLETED
Efficacy and Safety of VasoClip® vs. WeckClip® for Robotic Urologic Surgery
Incheon St.Mary's Hospital n=40
NCT04700124 COMPLETED
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
Merck Sharp & Dohme LLC n=808
NCT03898180 COMPLETED
Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)
Merck Sharp & Dohme LLC n=505
NCT03768414 COMPLETED
Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers
SWOG Cancer Research Network n=452
NCT03474107 COMPLETED
A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)
Astellas Pharma Global Development, Inc. n=608
NCT07279792 COMPLETED
Implications of Post-Operative Irrigation Fluid's Osmolarity on the Recurrence of Non-Muscle Invasive Bladder Cancer Following Transurethral Resection
Ain Shams University n=150
NCT04157985 COMPLETED
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
Dan Zandberg n=161
NCT03374488 COMPLETED
Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma
Incyte Corporation n=84
NCT03361865 COMPLETED
Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)
Incyte Corporation n=93
NCT04527991 COMPLETED
Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
Gilead Sciences n=712
NCT02807636 COMPLETED
Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Hoffmann-La Roche n=1,213
NCT04806178 COMPLETED
Immunological Response of Bladder Cancer Patients Under BCG
University of Campinas, Brazil n=30
NCT05600322 COMPLETED
Comparative Study of Hexvix Blue Light Cystoscopy and White Light Cystoscopy in the Detection of Bladder Cancer
Photocure n=158
NCT05136898 COMPLETED
Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)
UroGen Pharma Ltd. n=8
NCT02773849 COMPLETED
ADSTILADRIN (=INSTILADRIN) in Patients With High-Grade, Bacillus Calmette-Guerin (BCG) Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)
Ferring Pharmaceuticals n=157
NCT04209114 COMPLETED
A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer
Bristol-Myers Squibb n=114
NCT04688931 TERMINATED
A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
UroGen Pharma Ltd. n=282
NCT06301308 WITHDRAWN
A Novel Application of 2% Lidocaine Injection for Male Rigid cycstoscopy-a Patient-blinded Randomised Trial
Second Xiangya Hospital of Central South University
NCT02603432 COMPLETED
A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100)
Pfizer n=700
NCT04197986 TERMINATED
Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations
QED Therapeutics, a BridgeBio company n=39
NCT04066491 TERMINATED
Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC
EMD Serono Research & Development Institute, Inc. n=309
NCT02853305 COMPLETED
Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361)
Merck Sharp & Dohme LLC n=1,010
NCT02426125 COMPLETED
A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer
Eli Lilly and Company n=530
NCT02449239 COMPLETED
Vicinium Treatment for Subjects With Non-muscle Invasive Bladder Cancer Previously Treated With BCG
Sesen Bio, Inc. n=133
NCT03718754 COMPLETED
En-bloc vs Conventional Resection of Primary Bladder Tumor
David D'Andrea n=384
NCT02563561 TERMINATED
A Study of Intravesical Apaziquone as a Surgical Adjuvant in Participant Undergoing Transurethral Resection Bladder Tumor (TURBT)
Spectrum Pharmaceuticals, Inc n=62
NCT03224182 TERMINATED
A Study of Intravesical Qapzola (Apaziquone) as a Surgical Adjuvant in Participants Undergoing Transurethral Resection of Bladder Tumor (TURBT)
Spectrum Pharmaceuticals, Inc n=118
NCT03579758 WITHDRAWN
Chemotherapy Before & After Surgery in Patients With Resectable Gallbladder Cancer
Emory University
NCT03335059 TERMINATED
Mitomycin C Intravesical Chemotherapy in Conjunction With Synergo® Radiofrequency-Induced Hyperthermia for Treatment of Carcinoma in Situ Non-Muscle Invasive Bladder Cancer Patients Unresponsive to Bacillus Calmette-Guérin, With or Without Papillary Tumors.
Medical Enterprises Ltd. n=5
NCT02982395 TERMINATED
Study to Evaluate the Efficacy and Safety Of Intravesical Nanoxel®M In BCG Refractory NMIBC
Samyang Biopharmaceuticals Corporation n=36
NCT02660190 COMPLETED
Photodynamic Diagnosis (PDD) in Flexible Cystoscopy
Jørgen Bjerggaard Jensen n=696
NCT02240017 COMPLETED
A Study Evaluating Chemotherapy With Fractionated Cisplatin/Gemcitabine Versus Carboplatin/Gemcitabine in the Treatment of Advanced or Metastatic Urothelial Cancer With Impaired Renal Function.
Institut Claudius Regaud n=46
NCT02302807 COMPLETED
A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]
Hoffmann-La Roche n=931
NCT03298958 WITHDRAWN
Secondary Prevention Trial of Rapamycin in Patients With Resected Non-muscle Invasive Bladder Cancer
The University of Texas Health Science Center at San Antonio
NCT02560584 COMPLETED
A Study of Blue Light Flexible Cystoscopy With Cysview in the Detection of Bladder Cancer in the Surveillance Setting
Photocure n=304
NCT02471495 WITHDRAWN
RITE-EUROPE (Radiofrequency-Induced Thermochemotherapy Effect-EUROPE)
Medical Enterprises Europe B.V.

Data: ClinicalTrials.gov